ArticleJHEP reports : innovation in hepatology2026
Alcohol-driven phenotypic transition in MASLD and risk of liver-related events.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsChanges in the amount of alcohol consumption among individuals with steatotic liver disease (SLD) result in shifts between the phenotypes of metabolic dysfunction-associated SLD (MASLD), MASLD with increased alcohol intake (MetALD), and alcohol-related liver disease (ALD). Yet, real-world evidence on how these shifts affect the incidence of liver-related events (LREs) remains scarce. Therefore, we aimed to evaluate the impact of these dynamic subtype shifts on the risk of LREs.
methodsIn the nationwide cohort, 2,795,409 Korean adults who completed two consecutive biennial health examinations (2009-2010 and 2011-2012) were classified as MASLD, MetALD, or ALD at both assessments. Subtype transitions were determined based on fatty liver index-defined hepatic steatosis, cardiometabolic risk factors, and alcohol consumption. Participants were retrospectively followed from 2013 to 2022 for the occurrence of LREs, ascertained through diagnostic codes. Adjusted subdistribution hazard ratios (aSHRs) were calculated using the Fine-Gray model, accounting for death as a competing event.
resultsThe shift in SLD subtype from baseline to follow-up was closely aligned with corresponding changes in LRE risk. Individuals who remained in MASLD at both time points exhibited the lowest risk of composite LREs during the 9-year follow-up. In contrast, shifts from MASLD or MetALD to ALD were associated with the greatest escalation in LRE risk (MASLD-to-ALD: aSHR, 1.92 [95% CI, 1.83-2.02]; MetALD-to-ALD: aSHR, 1.27 [95% CI, 1.19-1.35]). Conversely, transitions toward MASLD were linked to substantial reductions in risk (MetALD-to-MASLD: aSHR, 0.89 [95% CI, 0.85-0.94]; ALD-to-MASLD: aSHR, 0.78 [95% CI, 0.73-0.83]).
conclusionsBecause dynamic changes in SLD subtypes strongly influence liver-related outcomes, regular reassessment of SLD classification is essential for timely and appropriate clinical management. IMPACT AND IMPLICATIONS: In this large, nationwide cohort of over 2.7 million Korean adults, we demonstrated marked heterogeneity in long-term liver outcomes according to dynamic steatotic liver disease subtype trajectories, providing strong scientific justification for monitoring disease evolution rather than relying on static classifications. These findings underscore the prognostic value of both alcohol intake reduction and metabolic risk management, highlighting the importance of integrated strategies for patients with hepatic steatosis. Clinicians and researchers should recognize the need for comprehensive care models that combine behavioral interventions such as alcohol screening, counseling, and referral to addiction services with pharmacological management of metabolic risk factors. Particularly, patients with MetALD and those with ALD represent highly vulnerable subgroups, underscoring the need for tailored strategies that address both alcohol use and metabolic dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.